๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 22 Shanghai 20 Hangzhou 12 Zhengzhou 12 Tianjin 9
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing22 Shanghai20 Hangzhou12 Zhengzhou12 Tianjin9
All 50 locations
Target enrolment
to

Trials with a site in Zhengzhou

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma
NCT06979869Esophageal Cancer
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yanโ€™an, Taiyuan, Chengdu
2025-05-26
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Recruiting
a Single-arm, Single-center, Open Clinical Study
NCT06431100Gastric Cancer, Esophageal Cancer, Cervical Cancer, Non-Small Cell Lung Cancer NSCLC
Beijing Geekgene Technology Co., LTD
Observational
10
Zhengzhou
2023-07-19
Recruiting
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
NCT06718205Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
112
Zhengzhou
2023-03-08
Recruiting
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
NCT05443841Esophageal Cancer
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Recruiting
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
NCT05182944Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
130
Zhengzhou
2022-01-15
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04280822Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Henan Cancer Hospital
Phase 3
400
Zhengzhou
2020-04-21
Recruiting
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT03736863Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
147
Zhengzhou
2019-12-05
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

12 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 12 studies
PhaseStudiesRecruitingShare
Phase 24433.3%
Observational3325%
Phase 12216.7%
Phase 1/22216.7%
Phase 3118.3%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Zhengzhou University33
Merck Sharp & Dohme LLC22
Ascentage Pharma Group Inc.11
Beijing Geekgene Technology Co., LTD11
Fudan University11
Henan Cancer Hospital11
Phrontline Biopharma11
Tianjin Medical University Cancer Institute and Hospital11
Xijing Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.